Ebelactone B, an inhibitor of extracellular cathepsin A-type enzyme, suppresses platelet aggregation ex vivo in renovascular hypertensive rats

Journal of Cardiovascular Pharmacology

Volumn 45, Issue 4, 2005, Pages 348-353

  Ostrowska, Halina ^a   Kalinowska, Joanna ^a   Chabielska, Ewa ^a   Stankiewicz, Adrian ^a   Kruszewski, Kamil ^a   Buczko, Wlodzimierz ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Cathepsin A; Ebelactone B; Platelet aggregation; Rat; Renovascular hypertension

Indexed keywords

ANGIOTENSIN I; BRADYKININ; CARBOXYPEPTIDASE C; COLLAGEN; EBELACTONE B; LACTONE DERIVATIVE; SERINE CARBOXYPEPTIDASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY THROMBOSIS; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; HYDROLYSIS; IN VITRO STUDY; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; RENOVASCULAR HYPERTENSION; SINGLE DRUG DOSE; THROMBOCYTE AGGREGATION INHIBITION;

ANIMALS; CARBOXYPEPTIDASE C; EXTRACELLULAR FLUID; HYPERTENSION, RENOVASCULAR; LACTONES; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RATS; RATS, WISTAR;

EID: 15744374879     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000157441.95354.d6     Document Type: Article

References (39)

1. Brown NJ, Vaughan DE. Prothrombotic effects of angiotensin. Adv Intern Med. 2000;45:419-429.
2. Weir MR, Dzan VJ. The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens. 1999;12:205S-213S.
3. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev. 1992;44:1-80.
4. Campbell DJ. The renin-angiotensin and the kallikrein-kinin systems. Int J Biochem Cell Biol. 2003;35:784-791.
5. Reilly CF, Tewksbury DA, Schechter NM, et al. Rapid conversion of angiotensin I to angiotensin II by neutrophil and mast cell proteinases. J Biol Chem. 1982;257:8619-8622.
6. Selak MA, Smith JB. Cathepsin G binding to human platelets. Evidence for a specific receptor. Biochem J. 1990;266:55-62.
7. Cerlerti C, Evangelista V, Molino M, et al. Platelet activation by polymorphonuclear leukocytes: Role of cathepsin G and P-selectin. Thromb Haemost. 1995;74:218-223.
8. Pshezhetsky AV. Lysosomal carboxypeptidase A. In: Barrett AJ, ed. Handbook of Proteolytic Enzymes. London: Academic Press, 1998, pp 393-398.
9. Jackman HL, Tan F, Schraufbagel D, et al. Plasma membrane-bound and lysosomal peptidases in human alveolar macrophages. Am J Respir Cell Mol Biol. 1995;13:196-204.
10. Skidgel RA, Erdös EG. Cellular carboxypeptidases. Immunol Rev. 1998;161:129-141.
11. Saito M, Majima M, Katori M, et al. Degradation of bradykinin in human urine by carboxypeptidase Y-like exopeptidase and neutral endopeptidase and their inhibition by ebelactone B and phosphoramidon. Int J Tissue React. 1995;17:181-190.
12. Jackman HL, Massad MG, Sekosan M, et al. Angiotensin 1-9 and 1-7 release in human heart. Role of cathepsin A. Hvpertension. 2002;39:976-981.
13. Erdös EG, Jackman HL, Brovkovych V, et al. Products of angiotensin I hydrolysis by human cardiac enzymes potentiate bradykinin. J Mol Cell Cardiol. 2002;34:1569-1576.
14. Giles AR. Guidelines for the use of animal in biomedical research. Thromb Haemost. 1987;58:1078-1084.
15. Huang WC, Ploth DW, Bell PD, et al. Bilateral renal function responses to converting enzyme inhibitor (SQ 20,881) in two-kidney, one clip Goldblatt hypertensive rats. Hypertension. 1981;3:285-293.
16. Zatz R. A low cost tail-cuff method for the estimation of mean arterial pressure in unconscious rats. Lab Anim Sci. 1990;40:198-201.
17. Guarini S. A highly reproducible model of arterial thrombosis in rats. J Pharmacol Topical Methods. 1996;35:101-105.
18. Kawasaki T, Sato K, Sakai Y, et al. Comparative studies of an orally-active factor Xa inhibitor, YM-60828, with other antithrombotic agents in a rat model of arterial thrombosis. Thromb Haemost. 1998;79:410-416.
19. Schumacher WA, Steinbacher TE, Heran CL, et al. Effects of antithrombotic drugs in rat model of aspirin-insensitive arterial thrombosis. Thromb Haemost. 1993;69:509-514.
20. Majima M, Ikeda Y, Kuribayashi Y, et al. Ebelactone B, an inhibitor of urinary carboxypeptidase Y-like kininase, prevents the development of deoxycorticosterone acetate-salt hypertension in rats. Eur J Pharmacol. 1995;284:1-11.
21. 1 on human platelet aggregation in whole blood in vitro. J Pharm Pharmacol. 1985;37:139-141.
22. Ostrowska H, Wojcik C, Omura S, et al. Lactacystin, a specific inhibitor of the proteasome, inhibits human platelet lysosomal cathepsin A-like enzyme. Biochem Biophys Res Commun. 1997;234:729-732.
23. Moore S. Amino acid analysis: aqueous dimethyl sulfoxide as solvent for ninhydrin reaction. J Biol Chem. 1968;243:6281-6283.
24. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
25. Bavry AA, Li D, Zander DS, et al. Inhibition of arterial thrombogenesis by quinapril but not losartan. Cardiovasc Pharmacol Ther. 2000;5:121-127.
26. Ostrowska H, Dabrowska M, Osada J, et al. Effects of ebelactone B on cathepsin A activity in intact platelets and on platelet activation. Roczniki Akademii Medycznej w Blalymstoku. 2003;48:150-153.
27. Moser L, Callahan KS, Cheung AK, et al. ACE inhibitor effects on platelet function in stages 1-11 hypertension. J Cardiovasc Pharmacol. 1997;30:461-467.
28. Lopez-Farre A, Sanchez de Miguel L, Monton M, et al. Angiotensin II AT (1) receptor antagonists and platelet activation. Nephrol Dial Transplant. 2001;16:45-49.
29. Chabielska E, Pawlak R, Golatowski J, et al. The antithrombotic effect of captopril and losartan on experimental arterial thrombosis in rats. J Physiol Pharmacol. 1998;49:251-260.
30. Chabielska E, Pawlak R, Wollny A, et al. Antithrombotic activity of losartan in two kidney, one clip hypertensive rats: a study on the mechanism of action. J Physiol Pharmacol. 1999;50:99-109.
31. Majima M, Katori M. Approaches of the development of novel antihypertensive drugs: crucial role of the renal kallikrein-kinin system. Trends Pharmacol Sci. 1995;16:239-246.
32. Nakajima S, Ito H, Hayashi I, et al. Inhibition of kinin degradation on the luminal side of renal tubules reduces high blood pressure in deoxycorticosterone acetate salt-treated rats. Clin Exp Pharmacol Physiol. 2000;27:80-87.
33. Jacob SW, Herschler R. Pharmacology of DMSO. Cryobiology. 1986;23:14-27.
34. Jackman HL, Tan F, Beurling-Harbury C, et al. A peptidase in human platelets that deamidatestachykinins. J Biol Chem. 1990;265:11265-11272.
35. Ostrowska H. Cathepsin A activity in thrombin-activated human platelets. Thromb Res. 1997;86:393-404.
36. Hanna WL, Turbov JM, Jackman HL, et al. Dominant chymotrypsin-like esterase activity in human lymphocyte granules is mediated by the serine carboxypeptidase called cathepsin A-like protective protein. J Immunol. 1994;153:4663-4672.
37. Jackman HJ, Morris PW, Rabito SF, et al. Inactivation of endothelin-1 by an enzyme of the vascular endothelial cells. Hypertension. 1993;21:925-928.
38. Miller JJ, Changaris DG, Levy RS. Conversion of angiotensin I to angiotensin II by cathepsin A isoenzymes of porcine kidney. Biochem Biophys Res Commun. 1988;154:1122-1129.
39. Hinek A. Biological roles of the non-integrin elastin/laminin receptor. Biol Chem. 1996;377:471-480.